Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 4/20 | 1.00 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.77 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.77 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.63 |
| ▸ | TERT | O14746 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | CBR1 | P16152 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18327173 | 0.88 | MEN1 (0.79) | FADS1P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL11932152 | 0.87 | P2RX1 (1.00) | FADS1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL330755 | 0.87 | FADS1 (0.77) | FADS1P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL15778718 | 0.85 | FADS1 (0.74) | FADS1P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL5631068 | 0.84 | P2RX1 (0.77) | FADS1P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL4372468 | 0.83 | P2RX1 (0.71) | FADS1P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL2129113 | 0.83 | FADS1 (0.71) | FADS1P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL472983 | 0.83 | FADS1 (0.78) | FADS1P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL15778871 | 0.83 | FADS1 (0.70) | FADS1P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL2308674 | 0.83 | FADS1 (0.70) | FADS1P2RX1P2RX4P2RX7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395210-A1 | INHIBITION OF BACTERIAL CHAPERONIN SYSTEMS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2021-12-23 | — | — | US | disclosed |
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
| EP-2047850-A2 | Methods for treating diseases through inhibition of the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | Romark Laboratories, L.C. (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-2047850-A2 | Methods for treating diseases through inhibition of the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | Romark Laboratories, L.C. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070015803-A1 | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | ROMARK LABORATORIES L.C. | 2007-01-18 | — | — | US | disclosed |
| US-20070015803-A1 | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | ROMARK LABORATORIES L.C. | 2007-01-18 | — | — | US | disclosed |
| US-20070015803-A1 | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | ROMARK LABORATORIES L.C. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395210-A1 | INHIBITION OF BACTERIAL CHAPERONIN SYSTEMS | HSP90B1, HSP90AB1, HSP90AB2P | FADS1 3386/4885P2RX1 3314/4885P2RX4 3806/4885 |
| US-20070015803-A1 | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents | HSP90B1, HSPA5, P4HB | FADS1 3918/4885P2RX1 2998/4885P2RX4 3185/4885 |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | PYGL, GYS2, GLS2 | FADS1 885/4885P2RX1 3603/4885P2RX4 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.